- Home
- FIHL vs VRDN Comparison
FIHL vs VRDN Comparison
Compare FIHL & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIHL
- VRDN
- Stock Information
- Founded
- FIHL 2014
- VRDN 2006
- Country
- FIHL Bermuda
- VRDN United States
- Employees
- FIHL N/A
- VRDN N/A
- Industry
- FIHL
- VRDN Medical Specialities
- Sector
- FIHL
- VRDN Health Care
- Exchange
- FIHL Nasdaq
- VRDN Nasdaq
- Market Cap
- FIHL 1.8B
- VRDN 1.6B
- IPO Year
- FIHL 2023
- VRDN N/A
- Fundamental
- Price
- FIHL $15.01
- VRDN $15.94
- Analyst Decision
- FIHL Buy
- VRDN Buy
- Analyst Count
- FIHL 8
- VRDN 12
- Target Price
- FIHL $20.63
- VRDN $36.44
- AVG Volume (30 Days)
- FIHL 782.1K
- VRDN 941.1K
- Earning Date
- FIHL 02-25-2025
- VRDN 05-07-2025
- Dividend Yield
- FIHL 2.67%
- VRDN N/A
- EPS Growth
- FIHL N/A
- VRDN N/A
- EPS
- FIHL 0.98
- VRDN N/A
- Revenue
- FIHL $2,420,000,000.00
- VRDN $302,000.00
- Revenue This Year
- FIHL N/A
- VRDN N/A
- Revenue Next Year
- FIHL $8.90
- VRDN $16,835.55
- P/E Ratio
- FIHL $15.31
- VRDN N/A
- Revenue Growth
- FIHL 23.65
- VRDN N/A
- 52 Week Low
- FIHL $14.17
- VRDN $11.40
- 52 Week High
- FIHL $21.32
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- FIHL 41.68
- VRDN 43.73
- Support Level
- FIHL $14.57
- VRDN $14.81
- Resistance Level
- FIHL $16.02
- VRDN $15.70
- Average True Range (ATR)
- FIHL 0.61
- VRDN 0.88
- MACD
- FIHL 0.02
- VRDN 0.06
- Stochastic Oscillator
- FIHL 35.31
- VRDN 64.73
About FIHL Fidelis Insurance Holdings Limited
Fidelis Insurance Holdings Ltd is a global (re)insurance company. It classify the business into three underwriting segments, namely Bespoke, Specialty and Reinsurance. Specialty primarily comprises property D&F, energy, marine and aviation lines. Bespoke primarily comprises credit and political risk and other tailored solutions for clients including transactional liabilities and credit insurance. Reinsurance primarily comprises property reinsurance.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.